Murray, Brion W.

SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase

Bennett, B. L., Sasaki, D. T., Murray, B. W., O'Leary, E. C., Sakata, S. T., Xu, W., Leisten, J. C., Motiwala, A., Pierce, S., Satoh, Y., et al. (2001) · Proceedings of the National Academy of Sciences

Protein Kinase Regulation and GTPase SignalingNF-κB Signaling Pathways

Cited by 2,558

Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance

Chen, P., Lee, N. V., Hu, W., Xu, M., Ferre, R. A., Lam, H., Bergqvist, S., Solowiej, J., Diehl, W., He, Y.-A., et al. (2016) · Molecular Cancer Therapeutics

Advanced Breast Cancer TherapiesComputational Drug Discovery Methods

Cited by 444

Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance

Schwartz, P. A., Kuzmic, P., Solowiej, J., Bergqvist, S., Bolanos, B., Almaden, C., Nagata, A., Ryan, K., Feng, J., Dalvie, D., et al. (2014) · Proceedings of the National Academy of Sciences

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 281

Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation

Pemovska, T., Johnson, E., Kontro, M., Repasky, G. A., Chen, J., Wells, P., Cronin, C. N., McTigue, M., Kallioniemi, O., Porkka, K., et al. (2015) · Nature

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 234

Discovery of N-((3 R,4 R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1 H-pyrazol-4-yl)amino)-9-methyl-9 H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR

Planken, S., Behenna, D. C., Nair, S. K., Johnson, T. O., Nagata, A., Almaden, C., Bailey, S., Ballard, T. E., Bernier, L., Cheng, H., et al. (2017) · Journal of Medicinal Chemistry

Lung Cancer Treatments and MutationsComputational Drug Discovery Methods

Cited by 97